Dermata Therapeutics to Present Phase 3 Acne Program Update at Maxim Healthcare Virtual Summit
核心洞察
Dermata Therapeutics CEO Gerry Proehl will present at the 2024 Maxim Healthcare Virtual Summit on October 15, 2024, at 3:30 PM ET.
The presentation will focus on providing an update on Dermata's Phase 3 acne (搜索) program, followed by a Q&A session.
Dermata Therapeutics is a late-stage biotechnology company focusing on medical and aesthetic skin diseases, with lead product candidate DMT310 for acne (搜索), rosacea (搜索), and psoriasis (搜索).
Dermata Therapeutics, Inc. (NASDAQ: DRMA), a late-stage biotechnology company focused on medical and aesthetic skin diseases, announced that CEO Gerry Proehl will present at the 2024 Maxim Healthcare Virtual Summit on October 15, 2024, at 3:30 PM ET. The presentation will provide an update on the company's Phase 3 acne (搜索) program.
Presentation Overview
Mr. Proehl's presentation will cover the progress of Dermata's Phase 3 clinical trials for its lead product candidate, DMT310, in acne (搜索) treatment. Following the presentation, a Q&A session will allow attendees to engage with Mr. Proehl and learn more about Dermata's strategic initiatives and clinical development plans.
DMT310: A Novel Approach to Acne Treatment
DMT310, derived from a naturally sourced freshwater sponge (Spongilla), is a once-weekly topical product candidate with multiple unique mechanisms of action. It is currently being evaluated in a Phase 3 program for acne (搜索), rosacea (搜索), and psoriasis (搜索). The Spongilla technology platform represents a novel approach to addressing these skin conditions.
Dermata's Broader Pipeline
In addition to DMT310, Dermata is also developing DMT410, which utilizes the Spongilla technology for topical intradermal delivery of botulinum toxin. DMT410 is being explored for the treatment of hyperhidrosis (搜索) and various aesthetic skin conditions, expanding Dermata's focus within the dermatology space.